All In Biotech

Drug Trial Radar · NCT07244705

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Nov 2025

Primary completion

Apr 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Anbogen Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Fortrea
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg/kg IV infusion Q3W, in participants with pMMR/non-MSI-H colorectal cancer (CRC). It will also determine the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) of ABT-301. Participants will receive ABT-301 administered once daily (QD ±3 hours) or twice daily (Q12H ±3 hours, at least 9 hours apart) with water in 21-day treatment cycles. Tislelizumab 200 mg IV and bevacizumab 7.5 mg/kg IV Q3W will be given in both parts of the study.

Conditions

  • Colorectal Cancer (Diagnosis)
  • Colorectal Cancer Metastatic
  • Colorectal Cancer (CRC)
  • Immunotherapy

Interventions

  • ABT-301Drug

    ABT-301 is an oral histone deacetylase inhibitor (HDACi) administered in capsule form once daily (QD ±3 hours) or every 12 hours (Q12H ±3 hours, with at least 9 hours between doses) with water in 21-day treatment cycles. In Part 1 (dose-escalation phase), participants receive escalating doses of ABT-301 (50 mg QD, 100 mg QD, 50 mg Q12H, 150 mg QD, or 75 mg Q12H). Tislelizumab 200 mg and bevacizumab 7.5 mg/kg will be administered through IV infusion on Day 1 of every 21-day treatment cycle. This phase aims to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ABT-301 when combined with tislelizumab and bevacizumab. In Part 2 (dose-optimization phase), two ABT-301 doses/schedules will be selected for further evaluation of antitumor activity, safety, and tolerability in adults with pMMR/non-MSI-H colorectal cancer (CRC).

  • TislelizumabDrug

    Tislelizumab is a humanized immunoglobulin G4-variant monoclonal antibody (mAb) blocking programmed cell death protein 1 (PD-1). Tislelizumab 200 mg will be administered through IV infusion on Day 1 of every 21-day treatment cycle in combination with ABT-301 and bevacizumab throughout both parts of the study.

  • Bevacizumab (Avastin)Drug

    Bevacizumab (Avastin®) is a recombinant humanized monoclonal IgG1 antibody which binds to and neutralizes VEGF. Neutralization of VEGF by bevacizumab has been shown to inhibit the VEGF-induced proliferation of human endothelial cells in vitro and to decrease micro-vessel density and interstitial pressure in tumor xenografts in vivo. Bevacizumab 7.5 mg/kg will be administered through IV infusion on Day 1 of every 21-day treatment cycle in combination with ABT-301 and tislelizumab, throughout both parts of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I - To evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg/kg IV infusion Q3W, in participants with pMMR/non-MSI-H CRC.Time frame: From screening to 90 days after last dose
  2. Part I - To determine the Maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) of ABT-301.Time frame: From the first dose of ABT-301 to the completion of the first 21-day cycle of ABT-301 treatment in the last cohort.
  3. Part II - To evaluate the efficacy of two dosages/schemes of ABT-301 in combination with tislelizumab and bevacizumab.Time frame: From baseline until progression of disease or death, whichever occurs first. (up to 28 months)

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Liverpool Cancer Therapy Centre

    Liverpool, New South Wales, Australia · Not yet recruiting

  • Macquarie University Hospital (MUH)

    Macquarie Park, New South Wales, Australia · Not yet recruiting

  • Scientia Clinical Research

    Randwick, New South Wales, Australia · Recruiting

  • Greenslopes Private Hospital - Cyril Gilbert Cancer Centre

    Greenslopes, Queensland, Australia · Not yet recruiting

  • The Queen Elizabeth Hospital (TQEH)

    Woodville South, South Australia, Australia · Not yet recruiting

  • Monash University - Faculty of Medicine, Nursing and Health Sciences

    Clayton, Victoria, Australia · Not yet recruiting

  • Austin Health - Cancer Clinical Trials Centre (CCTC)

    Heidelberg, Victoria, Australia · Not yet recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Not yet recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan · Not yet recruiting

  • E-Da Cancer Hospital

    Kaohsiung City, Taiwan · Not yet recruiting

  • Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan · Not yet recruiting

  • Taipei Medical University Shuang Ho Hospital, Ministry of Health and Welfare

    New Taipei City, Taiwan · Not yet recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Not yet recruiting

  • National Taiwan University Hospital - Cancer Center

    Taipei, Taiwan · Not yet recruiting

  • Chang Gung Medical Foundation, Linkou Chang Gung Memorial Hospital

    Taoyuan, Taiwan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.